Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Alfred Rosche

Interventional Pain Medicine Roscoe, IL Medical Doctor

NPI 1962448332 CMS profile 134012

Northpointe Clinic, 5605 E Rockton Road, Roscoe, IL 61073

Open in the dashboard

General payments

$5,451

169 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Alfred Rosche of Roscoe, IL is reported in the CMS Open Payments database as having received $5,451 across 169 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 58th percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $885 42
2024 General $3,216 48
2023 General $336 20
2022 General $133 6
2021 General $356 20
2020 General $170 10
2019 General $355 23

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Alfred Rosche
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Alfred Rosche were reported at $885. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Alfred Rosche Interventional Pain Medicine median Middle half National median
2019 $355 $684 $216–$2,079 $163
2020 $170 $382 $122–$1,109 $114
2021 $356 $552 $167–$1,554 $132
2022 $133 $605 $187–$1,924 $149
2023 $336 $671 $195–$1,915 $160
2024 $3,216 $684 $206–$1,837 $164
2025 $885 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Spinal Simplicity, LLC $1,919 21 payments
  2. Boston Scientific Corporation $954 18 payments
  3. Pfizer Inc. $702 44 payments
  4. Collegium Pharmaceutical, Inc. $464 25 payments
  5. Stryker Corporation $307 4 payments
  6. Amgen Inc. $177 12 payments
  7. Abbott Laboratories $106 3 payments
  8. Curonix LLC $98 1 payment
  9. Kowa Pharmaceuticals America, Inc. $89 6 payments
  10. Fidia Pharma USA Inc. $87 4 payments
  11. Other $548 31 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,555 161 payments
  2. Travel and Lodging $1,896 8 payments
Products named General payments · program years 2019–2025
  1. HA MINUTEMAN G3-R $1,919 21 payments
  2. LIBERTY SI $521 2 payments
  3. NURTEC ODT $442 27 payments
  4. OPTABLATE $277 3 payments
  5. SPINEJACK $277 3 payments
  6. Nucynta $189 10 payments
  7. ZAVZPRET $145 8 payments
  8. Intracept RF Probe $140 2 payments
  9. XTAMPZA $121 6 payments
  10. LYRICA $117 9 payments
  11. Other $2,348 127 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 32 drugs

Part D claims

7,717

Median for Pain Management: 951

Drug cost

$343,080

Median for Pain Management: $26,034

Branded share of claims

35.7%

Median for Pain Management: 29.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Nucynta Er Tapentadol Hcl Brand 58 $77,096
Fentanyl Generic 613 $75,125
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 1,951 $57,225
Oxycontin Oxycodone Hcl Brand 45 $25,334
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 617 $19,239
Methadone Hcl Generic 695 $18,772
Nucynta Tapentadol Hcl Brand 13 $17,802
Xtampza Er Oxycodone Myristate Brand 31 $15,532
Gabapentin Generic 831 $10,060
Tizanidine Hcl Generic 460 $5,171

The 10 drugs with the highest cost, of 32 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,732 Part D prescribers listed as Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 39 billing codes

Paid by Medicare

$80,453

Medicare's payments for the services billed

Medicare patients

350

Average age 71

Services billed

1,517

217 women, 133 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 74%
Diabetes 30%
Ischemic heart disease 27%
Depression 25%
COPD 21%
Heart failure 17%
Chronic kidney disease 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 7 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
NURTEC ODT
  • PFIZER INC. $169
$169 — —
Nucynta
  • Collegium Pharmaceutical, Inc. $72
$72 71 —
ZAVZPRET
  • PFIZER INC. $39
$39 — —
SPRAVATO
  • Janssen Pharmaceuticals, Inc $18
$18 — —
ZTLido
  • Scilex Pharmaceuticals Inc. $13
$13 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 7 in the dashboard with a free account

Records

169 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record